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Abstract 
Nearly 85% of acute heart failure (AHF) patients who present to the emergency department 
(ED) with acute heart failure are hospitalized. Once hospitalized, within 30 days post-discharge, 
27% of patients are re-hospitalized or die. Attempts to improve outcomes with novel therapies 
have all failed. The evidence for existing AHF therapies are poor: No currently used AHF 
treatment is known to improve long-term outcomes. ED treatment is largely the same today as 
40 years ago. Admitting patients who could have avoided hospitalization may contribute to 
adverse outcomes. Hospitalization is not benign; patients enter a vulnerable phase post-
discharge, at increased risk for morbidity and mortality. When hospitalization is able to be 
shortened or avoid completely, certain risks can be mitigated, including risk of medication 
errors, in-hospital falls, delirium, nosocomial infections, and other iatrogenic complications. 
Additionally, patients would prefer to be home, not hospitalized. Furthermore, hospitalization 
and re-hospitalization for AHF predominantly affects patients of lower socioeconomic status 
(SES). Avoiding hospitalization in patients who do not require admission may improve outcomes 
and quality of life, while reducing costs.  
 
Short stay unit (SSU: less than 24 hours, also referred to as an ‘observation unit’) management 
of AHF may be effective for lower risk patients. However, to date there have only been small 
studies or retrospective analyses on the SSU management for AHF patients. In addition, SSU 
management has been considered ‘cheating’ for hospitals trying to avoid 30-day readmission 
penalties, as SSUs or observation units do not count as an admission. However, more recent 
analyses demonstrate differential use of observation status has not led to decreases in re-
admission, suggesting this concern may be misplaced. Thus, we propose a robust clinical 
effectiveness trial to demonstrate the effectiveness of this patient-centered strategy. 
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Background 
Heart failure (HF) accounts for a large burden on the healthcare industry, both in terms of 
volume of emergency department (ED) visits and hospitalizations, as well as associated costs. 
Already, 6.5 million Americans are affected with HF. By 2030, prevalence is expected to 
increase by 25%.1,2 Nearly $21 billion was spent on HF in 2012; by 2030 HF will cost over $53 
billion per year.1 For acute heart failure (AHF) patients, approximately 80-85% of patients 
presenting to the ED are hospitalized.3 Hospitalization accounts for the vast majority of related 
expenditures.1 Over time, the ED has evolved as the primary source of hospital admissions for 
AHF.4 Thus, safely reducing admissions from the ED may be one pathway to reduce the cost 
burden of AHF. While improved primary care access and broader health insurance coverage 
are appealing solutions, early reports suggest enhanced insurance coverage may be associated 
with greater ED utilization by all patients, including those with AHF.5,6 Therefore, differentiating 
patients with AHF who require admission versus direct ED discharge or a brief period of 
observation, may help improve outcomes while reducing costs. 
 
Rationale for the Short Stay Unit (SSU) – AHF Trial 
Accurate and effective tools to identify patients with high-risk features of AHF, namely those 
with renal dysfunction, unstable vital signs, and elevated biomarkers such as natriuretic peptide 
and troponin have been developed.7-11 Such patients often require hospitalization. However, 
absence of higher risk features has yet to translate into low-risk characteristics identifying 
patients safe for direct ED discharge. Previous studies define low-risk as a low probability of re-
admission within 30 days, or those having very low (< 1.0%) predicted mortality.12,13 Thus far, 
the impact of such low-risk tools on ED provider decision making has been minimal. This is a 
result of limited implementation and evaluation of how these tools would impact real-time 
provider decision making and their association with patient outcomes. Furthermore, such 
studies are commonly retrospective, lack external validation, or are not well tested in a United 
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States patient cohort. Given these limitations, SSUs have emerged as an appealing alternative 
to direct ED discharge of patients, offering a measure of assurance for ED physicians who are 
uncomfortable with direct discharge. The SSU, also referred to as a clinical decision or 
observation unit, allows for additional evaluation and management of patients who do not meet 
high-risk criteria for inpatient admission. However, the lack of high-risk features does not 
necessarily indicate that the patient is of low-risk status. Prior studies defining low-risk markers 
have not been extensively test.14,15,16 Thus, a lack of high-risk features suggests they may be 
good SSU candidates for a period of observation. The goals are: 1) achieve safe, on-going care 
for patients not-yet-ready for discharge 2) avoid added cost or family caregiver burden 
compared to inpatient admission.  
 
While randomized, controlled trials of SSU care for AHF have yet to be conducted, several 
observational studies demonstrate the value of SSUs (Table 1). A retrospective study of 358 
AHF patients demonstrated no increase in 30-day or 90-day readmission rates among patients 
who were cared for in an SSU compared to hospitalized patients, providing an important safety 
signal.
17
 Other smaller studies suggest improved outcomes and reduced costs relative to 
inpatient admission.18 However, absent sufficiently powered, prospective, randomized studies, 
the likelihood of widespread adoption is limited. To address this gap, we designed a randomized 
trial that seeks to better characterize SSU outcomes in patients with AHF, and simultaneously 
improve the evidence base for HF guidelines in this cohort. Our study has two principle aims: 1) 
the primary aim is to demonstrate the effectiveness of an SSU AHF management strategy, as 
compared to usual AHF care (i.e. inpatient admission) using days-alive-and-out-of-the-hospital 
(DAOOH); 2) secondary aims include evaluating differences in quality of life (QoL) scales as 
outcome measures; and adherence to HF guidelines at the time of discharge when compared to 
discharge from usual care (i.e. inpatient admission).   
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Methods 
The SSU trial is a prospective, 1:1 randomized, controlled, comparative effectiveness study of a 
strategy of care (SSU care) vs. usual care (inpatient admission). Eligible subjects will be ED 
patients with AHF who would typically be admitted under usual care by the ED treatment team 
and who lack baseline high-risk features. 
 
Study Population  
A total of 526 patients at 4 sites will be enrolled over 4.5 years. As a contingency plan, if 
additional study sites are needed to meet our enrollment targets, we plan to convert our budget 
to a per-patient payment, allowing us to easily double our number of enrolling sites. All patients 
will provide written informed consent. Patients who present to the ED with signs or symptoms of 
AHF will be screened during times when research staff are available. Each site has distinct 
coverage ranging from 8 to 24 hours a day. Eligibility criteria (Table 2) are based on clinical 
stability, a prior HF history and no high-risk features or active comorbidities that would 
complicate their SSU stay. However, the initial ED management plan for patients must be 
intended inpatient admission. As a comparative effectiveness trial, the inclusion/exclusion 
criteria are relatively broad compared to other therapeutic clinical trials. Patients will be 
identified by dedicated, trained, experienced research personnel stationed in the participating 
EDs, utilizing electronic screening of ‘tracking boards’ in the ED, alert systems generated by the 
electronic health record, and direct interaction with members of the ED clinical care team. 
Patients with AHF are first pre-screened to determine if eligibility criteria are met; however, only 
after written informed consent will randomization occur. In accordance with prior observation 
unit guidelines, patients will not be excluded purely based on severely reduced ejection 
fraction.13 
 
Study Treatment  
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Patients will be randomized 1:1 to either Arm 1. SSU AHF Strategy or Arm 2. Usual Care 
(defined by routine inpatient admission), but stratified by site to ensure equal site 
representation. A central computer-generated randomization scheme with random block sizes of 
two, four, and six will be created. The REDCap randomization module will be utilized to 
generate the randomization schema and patient allocation. 
 
Those randomized to Arm 1 will receive AHF care in the SSU, with a recommended study 
treatment protocol based on guideline recommendations.13 These patients will be assessed 
upon arrival to the SSU with quantification of urine output, systolic blood pressure, and signs 
and symptoms of volume overload. Importantly, there is significant latitude allowed for 
caregivers in the SSU to better reflect ‘real-world’ SSU practice. In the event that the SSU is at 
full bed capacity, the protocol can be initiated from the ED, until an SSU bed becomes available. 
Those patients with signs of total body volume overload and less pulmonary edema who 
warrant further treatment will be categorized as volume overload (‘cardiac type’). Alternatively, 
patients will be categorized as ‘vascular type’ when hypertens ion predominates and symptoms 
occur over a shorter period of time, with less peripheral edema and weight gain, and more 
pulmonary congestion often due to vascular redistribution and not volume accumulation.19 
‘Cardiac type’ patients will be treated primarily with IV loop diuretics. ‘Vascular type’ patients will 
be treated with an emphasis on vasodilators such as topical and sublingual nitroglycerin, as 
vascular redistribution is often a large contributor to symptoms, in addition to IV loop diuretics.   
Frequent reassessment aimed to aggressively, but safely, decongest patients will occur in the 
SSU arm.20,21  
 
Once hemodynamic symptomatic improvement has been achieved, monitoring can be 
deescalated to every 6-8 hours with recommended scheduled doses of IV furosemide at 8-hour 
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intervals. Patients will be deemed stable for discharge per the recommended criteria listed in 
Table 3. These discharge criteria are based on the American College of Cardiology’s 
Accreditation Services (formerly known as the Society of Cardiovascular Patient Care) short-
stay AHF management recommendations.13,22 Arm 2 (inpatient admission) subjects will continue 
on their originally planned care pathway of hospitalization, representing the ‘usual care’ 
comparator arm. Inpatient hospital admission is the most common approach to patients who 
present to the ED with signs of an AHF exacerbation.3 Therefore, subjects randomized to Arm 2 
will be treated according to management offered to AHF patients admitted to the hospital. Care 
in the inpatient arm will be at the discretion of the inpatient admitting team.  
 
Data Collection and End Points 
The primary endpoint of this study is the number of DAOOH at 30 days following discharge, 
accounting for both frequency and duration of hospitalizations (Tables 4 and 5). This data will be 
collected by hospital electronic medical record chart review, as well as telephone calls to 
patients at 30- and 90- days. Those patients who experience death during hospitalization will be 
counted as zero DAOOH. Secondary endpoints include QOL and a cost-effectiveness analysis 
between the two arms at 30 days. QOL will be measured by the Kansas City Cardiomyopathy 
Questionnaire (KCCQ), a patient-reported survey designed to measure QOL in HF patients, 
where lower scores indicate lower QOL. To ensure feasibility we previously piloted the KCCQ in 
ED patients with AHF.23 Exploratory endpoints include: 1) caregiver burden, as measured by 
two separate caregiver burden instruments (Bakas Caregiving Outcomes Scale and the Oberst 
Caregiving Burden Scale) [See Appendix] ; 2) cost-effectiveness of the SSU AHF strategy of 
care at 90 days; 3) resource utilization measured by the Modified Resource Utilization 
Questionnaire for Heart Failure (mRUQ-HF) at 90 days; 4) all-cause mortality at 30 and 90 
days; 5) all-cause re-hospitalization at 30 and 90 days; 6) DAOOH at 90 days; and 7) HF 
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Guideline medication adherence at 30 days. The primary and secondary endpoints will be 
collected by study team members who are blinded to study arm.  
 
Cost Effectiveness Analysis (CEA) 
Cost will be defined as broadly as possible, to capture not only monetary costs as part of the 
SSU treatment, but also costs associated with follow up care, as captured by all sources of 
payment. In addition to the KCCQ, we will also measure quality of life using the SF-12. The SF-
12 will be converted into the SF-6D, allowing direct assessment of Quality Adjusted Life Years 
(QALYs) necessary for the CEA. The SF-6D allow for the generation preference weights and 
probabilities necessary to conduct the cost-utility analysis. Since the participant will be 
completing the SF-12 survey at the beginning and end of the episode, all models estimating the 
effectiveness will include the baseline score in the vector of participant characteristics. 
Multinomial regression analysis will be conducted to assess the impact of the SSU stay on 
these outcomes of interest, adjusting for patient characteristics which might predispose 
treatment intensity and, thus, costs. 
We have requested from each participating hospital information about the reimbursement and 
payment received for each episode of treatment. Combined with the patient insurance 
information, this will allow us to estimate per episode patient, private insurance, and public 
insurance cost of delivery of care. Because the duration of SSU and usual treatment are not 
comparable, we will, instead, compare total per patient cost, combining all admissions and 
readmissions for each study arm.   
Furthermore, the mRUQ-HF questionnaire will include information about out of hospital 
healthcare utilization, allowing us to estimate the additional costs of non-hospital care using a 
Medicare cost dictionary for an approximate outpatient care associated with each study arm. 
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Statistical Analysis and Power Calculations  
Assuming a 10% attrition rate, we will randomize 534 patients 1:1, which will provide 80% power 
(alpha 0.05, two-sided) to demonstrate a one-day difference in the primary outcome at 30 days 
post-randomization. The primary analyses will be performed in accordance with the intent-to-
treat principle. Patients will be analyzed according to the group to which they were randomized. 
A per-protocol analysis will also be performed as a secondary analysis, for which patients will be 
analyzed by the treatment group where they ultimately were managed. In the per-protocol 
analysis, those patients who crossed over to the inpatient arm after randomization would be 
analyzed in the inpatient arm. Analysis of the primary endpoint will entail description of 
continuous data using means (standard deviations) or medians (interquartile range), while 
categorical data will be described using frequency and percentages. Group comparisons of 
continuous variables will be drawn from either two-sample t-tests, or Wilcoxon’s Rank Sum test 
for variables that do not appear normally distributed. Categorical data comparisons will be 
presented based on the Chi-square, or Fisher’s exact test if any cell counts are below 5. The 
analysis of our secondary endpoints will involve review of the KCCQ data, as well cost-
effectiveness analysis. The KCCQ scores will be compared amongst the two arms using three 
different methods. First, we will exclude subjects who die without KCCQ in the analysis. 
Second, we will set KCCQ=0 for those who die without the 30-day KCCQ and include these 
people in the analysis. Third, we will create a composite binary endpoint of KCCQ<c or death, 
where c is a threshold. The chi-square test and logistic regression will be used to compare this 
outcome. We will select several relevant values for the threshold c and tabulate the results. The 
three analysis schemes allow us to understand how robust the comparison of KCCQ is with 
respect to different treatments of death. Exploratory endpoints analysis will also be performed. 
The analysis of caregiver burden will be similar to the KCCQ analysis described above, using 
both caregiver survey instruments. Resource utilization will be measured by the mRUQ-HF, a 
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14-item self-questionnaire related to healthcare utilization. The mRUQ measures costs from a 
societal perspective, involving an assessment of resources consumed. 
 
Discussion 
Significant resources have been allocated to establish methodologies for identifying patients 
who are high-risk for readmission, as well as risk factors for poor outcomes.14,16,24 This is a 
particularly common challenge among the HF patient population, as HF is the leading cause of 
readmissions among Medicare beneficiaries.25 In an effort to reduce readmission rates to the 
hospital, penalties have been implemented and directed at hospitals with higher than expected 
HF readmission rates. Despite the assumption that higher quality of care will reduce 
readmission rates, little to no correlation exists between readmission rates and quality of care.26 
In fact, readmission rates appear to correlate with regional readmission trends rather than 
quality of care provided.27 This suggests care provided in short stay units and readmission rates 
may be independent of one another.  
 
Hospitals have developed strategies to minimize readmissions as a direct response to the 
Hospital Readmission Reduction Program. It has been suggested that some hospitals or health 
care systems may be ‘gaming the system’ to avoid readmission penalties by placing patients in 
observation status.28 However, an analysis of Medicare beneficiaries demonstrates no 
association between decreased readmissions and increased utilization of observation status.28 
We designed our study to ensure quality care is delivered with the goal of not necessarily 
reducing 30-day readmissions, but rather providing care in a more timely and cost-effective 
manner, with 30-day outcomes similar to an inpatient admission. In other words, the SSU 
facilitates continued high-quality patient care, while minimizing the financial and resource 
burdens associated with inpatient management. Ultimately, if patients require a longer treatment 
course, they should and will be hospitalized, demonstrating the versatility and inherent safety of 
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an observation unit-based protocol. However, the potentially high observation to inpatient ratio 
may lead some health systems to hesitate to implement an observation unit HF pathway. This 
study will help address this concern. 
 
Historical and objective exam, laboratory and imaging findings will be used to identify AHF 
patients prior to SSU entry.29 The ability to further monitor patients in a SSU may provide a safe 
alternative for those who have no high-risk features but for whom it is unclear if they are truly 
low-risk.13,22,29 We have based our entry criteria on prior studies and consensus 
recommendations for identifying candidates suitable for entry to an SSU. The American College 
of Cardiology’s Accreditation Services has offered guidance for these criteria, focusing on data 
both at time of presentation to the ED, as well as after initial therapy has been administered.13 
Specifically, this committee recommended patients with renal dysfunction, hyponatremia, 
hypotension, ischemic changes on ECG, or elevated cardiac troponin should be admitted to the 
hospital for monitoring and treatment in an inpatient bed (Category B recommendation).
13
 Thus, 
we have excluded these higher-risk patients. These patients have been identified by the 
following criteria, outlined in Table 6. 
 
Conclusions 
Hospitalization for AHF results in a significant financial healthcare burden. Safely reducing costs 
while maintaining quality is essential. Reducing admission from the ED is one potential strategy. 
Prior studies suggest SSU management of AHF is both cost-effective and equivalent in the 
degree of quality of care provided when compared to those admitted to the hospital. However, 
those studies were limited by non-experimental designs and small samples. Thus, we have 
designed the SSU-AHF to fill this knowledge gap. Patients with AHF will be readily identified 
during the initial phase of ED evaluation based on bedside assessment and results of ED 
testing. We will then utilize a randomized controlled trial design to further evaluate the efficacy 
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of SSU management in terms of 30- and 90- day outcomes, with particular interest in the 
quantity of time patients remain outside of the hospital following SSU discharge and how this 
impacts resource utilization and QOL. If this proposal confirms our hypothesis, further evidence 
will be available in support of SSU as an alternative to inpatient admission for low-risk patients 
with AHF who meet specific criteria. This would allow for further development of formal 
guidelines for such patients presenting to the ED with AHF. 
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Table 2: Eligibility Criteria 
Inclusion 
1) ED physician clinical diagnosis of AHF;  
2) Planned admission for AHF by the 
treating ED team 
3) Systolic blood pressure > 115mmHg*, 
heart rate < 115bpm, Oxygen saturation 
> 93% on room air ;^  
4) Previous history of HF 
 
Exclusion 
1) Patients hospitalized within the last 30 
days ONLY if the institution mandates 
these patients are observed. Otherwise, 
these patients remain eligible. 
2) Transplanted organ of any kind or 
ventricular assist device patient;  
3) End stage renal disease, on dialysis, or 
eGFR < 30 mL/min;  
4) Acute coronary syndrome (e.g. EKG 
changes consistent with ischemia or 
troponin elevation secondary to ACS as 
per the treating ED clinician);  
5) Other acute co-morbid conditions (e.g. 
sepsis, altered mental status); 
6) Hemoglobin < 9, sodium < 135, BUN > 40, 
eGFR < 30;  
7) Patients who require ventilatory support of 
any kind or intravenous 
vasodilators/vasopressor/inotropic support 
at the time of ED disposition 
8) Pregnant patients or any patient who has 
been pregnant in the last 3 months 
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9) ≤ 18 years of age 
10) Any patient who in the opinion of the 
clinician or investigator should not be in an 
SSU or requires ICU level care or will 
require inpatient rehabilitation or skilled 
nursing facility after discharge from the ED 
or hospital 
11) Planned discharge from the emergency 
department  
12) De novo (new onset) AHF 
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Table 3 
 
SCPC Discharge OBS Criteria 
- 7-point Dyspnea Likert 
- Assessment of ambulatory status. Walk to the bathroom and back or up and down 
hall or other equivalent.   
o “How short of breath do you feel when walk around?” 
 Not short of breath at all 
 My usual or baseline SOB 
 Mildly Worse than my usual or baseline SOB 
 Moderately Worse than my usual or baseline SOB 
 Severely Worse than my usual or baseline SOB 
- Record of physical exam for rales, JVD, and peripheral edema. 
- Record of body weight at beginning and end of SSU/OBS stay 
- Record of ED labs and SSU/OBS unit labs 
- Question for practitioner: “was the cause of the patients decompensation 
identified?”  [YES/NO] 
- Question for practitioner: “To the extent possible, was the precipitant treated or 
reversed?”  [YES/ NO / Not able to be reversed or treated]  
- “Was patient transitioned from IV to oral diuretics?” [YES/NO]  
- “Was education performed?” [YES/NO]  
- “Did medicine reconciliation occur?”  [YES/NO]  
- “Was follow up visit arranged?  [Appt made for patient / Patient has to make their 
own appointment / No follow up arranged ] 
 
 
It is recommended at the time of discharge that change in symptoms of congestion, as 
measured by improvement in dyspnea, is documented. Level of Evidence: B 
- 7 point Likert Scale 
It is recommended at the time of discharge that the patient be able to ambulate without an 
exacerbation or recurrence of symptoms including significant dyspnea above baseline and 
orthostasis. Level of Evidence: B 
- assessment of ambulatory status. Walk to the bathroom and back or up and down 
hall or other equivalent.   
- “How short of breath do you feel when walk around?” 
o Not short of breath at all 
o My usual or baseline SOB 
o Mildly Worse than my usual or baseline SOB 
o Moderately Worse than my usual or baseline SOB 
o Severely Worse than my usual or baseline SOB 
 
At the time of discharge improvement in other signs such as decreased rales, edema, and 
jugular venous pressure, and a decrease in body weight should be considered as 
parameters of decreased congestion. Level of Evidence: B 
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- By discharge physical exam in notes/medical record 
 
It is recommended at the time of discharge that no significant alterations in serum 
electrolytes, with an emphasis on serum sodium and creatinine, are present. Level of 
Evidence: A 
- By discharge lab values 
 
It is recommended that prior to discharge several goals must be met including: 
- Question for practitioner: “was the cause of the patients decompensation 
identified?”  [YES/NO] 
- “To the extent possible, was the precipitant treated or reversed?”  [Yes/ No / Not 
able to be reversed or treated] 
- “Was patient transitioned from IV to oral diuretics?” [YES/NO]  
- “Was education performed?” [YES/NO]  
- “Did medicine reconciliation occur?”  [YES/NO]  
- “Was follow up visit arranged?  [Appt made for patient / Patient has to make their 
own appointment / No follow up arranged ] 
 
the reasons for acute decompensation have been identified and (partially) reversed; 
transition from intravenous to oral diuretic has been completed; patient and family 
education has been addressed; the initial outpatient pharmacologic regimen has been 
established; compliance with Joint Commission core measures for heart failure has 
occurred; and a follow-up clinic visit is arranged for between 7 and 10 days after discharge. 
Level of Evidence: C 
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Table 4. Primary, secondary and exploratory endpoints 
Primary Endpoint Secondary Endpoints Exploratory Endpoints 
Number of days 
alive and out of 
hospital at 30 days 
post-discharge 
 Quality of life1 
 Cost-
effectiveness 
between two 
arms at 30 days 
 Caregiver burden2 
 Cost-effectiveness of the SSU AHF 
strategy of care at 90 days 
 Resource utilization3 
 All-cause mortality at 30 & 90 days 
 All-cause re-hospitalization at 30 & 
90 days 
 Days alive and out of hospital at 90 
days 
 HF Guideline adherence at time of 
discharge 
1
 as measured by Kansas City Cardiomyopathy Questionnaire 
2
 as measured by Bakas Caregiving Outcomes Scale and the Oberst Caregiving 
Burden Scale  
3 as measured by the Modified Resource Utilization Questionnaire for Heart Failure 
(mRUQ-HF) 
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Table 5. Data collection time points through 90-day follow-up 
Schedule of Events 
Timepoint/Visit 
Scree
n 
Baseli
ne 
ARM 1 – 
Pre-
Discharge 
from SSU 
ARM 2 – 
Pre-
Discharge 
from 
Hospital 
Floor 
30 & 90 
Day 
Follow 
up 
Informed Consent X 
    
Medical History 
 
X 
   
Physical Exam 
 
X X X 
 
Clinical lab tests* 
 
X   X~   X~ 
 
ECG* 
 
X 
   
CXR* X 
   
KCCQ (QoL) & SF-12 
  
X X X 
Oberst Caregiving Burden Scale and 
Bakas Caregiving Outcomes Scale  
X X X  X1 
HF Guideline Assessment 
  
X X 
 
Collect concomitant meds 
 
X X X X 
mRUQ-HF (resource utilization)       X  ^
Cost Effectiveness Measures (i.e. 
DRG)     
X 
Guideline adherence assessment  X X X  X1 
SCPC Discharge Criteria Adherence   X X  
Assessment of AE/SAE's through 5     X X 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
days 
Vital Status, ED visits, Hospital days, 
Re-admission status 
    X X X 
*per standard of care. Typical labs include: Na, K, renal function, HgB, troponin, Natriuretic 
Peptide levels. ~only if performed per usual care 
SOC = standard of care, ED = Emergency Department,  QoL = quality of life, HF = heart failure, 
mRUQ = modified resource utilization questionnaire, EMR = electronic medical record, DRG = 
diagnosis related group 
1Only through 30 days 
o^nly at 90 days 
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Table 6: High-Risk Features13,15,27 
 New-onset HF 
 Vital signs: 
o Systolic blood pressure <85 mmHg or >175 mmHg 
o Heart rate >135 beats/min 
o Resp rate >32 breaths per minutes 
o Oxygen saturation <90% 
 Airway instability (need for >4L/min supplemental oxygen 
 Ischemic changes on ECG 
 Need for titratable IV infusions 
 Need for noninvasive ventilation  
 Signs of poor perfusion 
 Signs of altered mental status 
 Poor response to initial therapy  
 Renal dysfunction 
 Hyponatremia 
 Troponin >0.1 μg/L in the setting of normal renal function 
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